| Initiating ICS | Increasing ICS | |||
|---|---|---|---|---|
| EF HFA-BDP | FP | EF HFA-BDP | FP | |
| (n=4224) | (n=12,672) | (n=320) | (n=640) | |
| Achieved asthma control, n (%) | 2394 (56.7) | 7221 (57.0) | 171 (53.4) | 348 (54.4) |
| Achieved asthma control+SABA, n (%) | 1767 (41.8) | 4460 (35.2) | 136 (42.5) | 271 (42.3) |
| No severe exacerbations, n (%) | 3012 (71.3) | 8942 (70.6) | 222 (69.4) | 445 (69.5) |
| Achieved asthma control + no increase in therapy, n (%) | 2044 (48.4) | 6229 (49.2) | 168 (52.5) | 322 (50.3) |
| Controller–reliever ratio ≥0.5, n (%) | 3133 (74.2) | 8459 (66.8)* | 271 (84.7) | 533 (83.3) |
| MPR ≥80%, n (%) | 170 (4.0) | 593 (4.7) | 36 (11.3) | 72 (11.3) |
| Outcome year ICS dose, μg/d [Median (IQR)] | 44 (22–88) | 72 (36–145)* | 94 (44–175) | 145 (72–266)* |
*p≤0.05.